Etanercept is a recombinant fusion protein biologic therapeutic agent used to manage autoimmune conditions such as rheumatoid arthritis, plaque psoriasis, and ankylosing spondylitis by inhibiting tumor… Read more
Etanercept is a recombinant fusion protein biologic therapeutic agent used to manage autoimmune conditions such as rheumatoid arthritis, plaque psoriasis, and ankylosing spondylitis by inhibiting tumor necrosis factor (TNF). By binding specifically to TNF-alpha, this molecule effectively reduces the inflammatory processes that contribute to tissue damage. The provided range of Etanercept related compounds includes reference standards for the API, as well as necessary impurities, degradation products, and stable isotope-labelled compounds required for comprehensive analytical testing. Laboratories utilize these high-quality materials to facilitate rigorous impurity profiling, method validation, and ongoing quality control during the manufacturing and characterization of biologic drug substances. Accessing precise, well-characterized reference materials ensures consistent monitoring of product stability and potency throughout the drug lifecycle, supporting the stringent regulatory requirements essential for therapeutic protein development.